Skip to main content
Premium Trial:

Request an Annual Quote

CPGR, SimuGen Enter Into Biomarker Assay Pact

NEW YORK (GenomeWeb News) – South Africa's Centre for Proteomic and Genomic Research today said that it has entered into an agreement with SimuGen to develop biomarker assays for the prediction of toxicity of existing and new drug compounds.

SimuGen is a Malaysia-based pharmacogenomics firm working on novel dose-toxicity models for drug development customers.

"The work we will do with Simugen, aimed at improving the ability to develop novel, safe drugs, fits perfectly into our vision of creating cutting-edge ex-vivo drug screening workflows that make full use of our genomic and proteomic platforms," Reinhard Hiller, managing director of CPGR, said in a statement.

CPGR was founded in 2006 as a non-profit organization to provide South African scientists with analytical services, project support, and collaborative research capabilities in the genomics and proteomics fields. The organization has a particular interest in translational research and has branched out into molecular diagnostics and drug discovery.

Terms of the collaboration with SimuGen were not disclosed.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.